https://drugdiscoverytrends.com

Drug Discovery & Development | Pharma and Biotech InsightsStay updated with drug discovery trends on drugdiscoverytrends.com. Dive into pharma and biotech insights, from AI to neurological disease.Drug Discovery & Development | Pharma and Biotech Insights Drug Discovery and Development Home Drug Discovery and Development Drug Discovery Women in Pharma and Biotech Oncology Neurological Disease Infectious Disease Resources Video features Podcast Webinars Pharma 50 2024 Pharma 50 2023 Pharma 50 2022 Pharma 50 2021 Pharma 50 Scorpion’s STX-478 shows promising efficacy and tolerability in early cancer trialKisqali slashes recurrence risk by 28.5% in early breast cancerImportant ERP considerations for biotech manufacturersSt. Jude pioneers gene editing and structural biology to advance pediatric researchHow Fovus enabled a biotech to accelerate high-throughput screening by up to 96x with cloud HPCThe future of RWD and RWE in healthcare decision-making: Applications of novel real-world data collection methods for healthcare decision-makingHow DeepCure taps reinforcement learning for first-in-class therapiesEarli and Accenture partner in quest to turn cancer against itselfGene therapy yields 100x vision average improvement, with a few reaching 10,000xThe 50 largest pharmaceutical companies in the world50 of the best-selling pharmaceuticalsPharma’s top 25 R&D spenders in 2022Today on Drug Discovery & Development By Brian Buntz | September 16, 2024Scorpion’s STX-478 shows promising efficacy and tolerability in early cancer trialScorpion Therapeutics’ new oral cancer drug, STX-478, showed promising anti-tumor activity as a monotherapy in a Phase 1/2 trial, achieving an overall response rate (ORR) of 23% in breast cancer and 21% across all tumor types studied. The data were unveiled at the European Society for Medical Oncology (ESMO) Congress 2024, held 13–17 September 2024.…By Brian Buntz | September 16, 2024Kisqali slashes recurrence risk by 28.5% in early breast cancerUpdated results from the Phase 3 NATALEE trial reveal that Kisqali (ribociclib) significantly cut the risk of recurrence in patients with HR+/HER2- early breast cancer. Adding Kisqali to standard endocrine therapy (ET) resulted in a 28.5% reduction in invasive disease-free survival (iDFS) events compared to ET alone (HR=0.715; 95% CI: 0.609–0.840; P<0.0001), Novartis announced in…By Scott Ryan | September 16, 2024Important ERP considerations for biotech manufacturersManufacturers in the biotech sector face unique challenges ranging from stringent regulatory requirements to complex production processes. Implementing an ERP (enterprise resource planning) system tailored to their needs is crucial for ensuring compliance, efficiency, and scalability. Whether you are a life sciences CMO (contract manufacturing organization), a pharmaceutical manufacturer with an R&D department, or a…Read All Articles >Drug Discovery and Development See More >The roadmap to effective AI-driven drug developmentGenerative artificial intelligence (GAI) has captivated the world, and for good reason. Platforms like ChatGPT have demonstrated capabilities that gave the general public a deeper understanding of AI’s capabilities. AI, too, is showing potential in drug discovery. From designing novel drug molecules to predicting protein structures, AI is offering a new path forward, potentially accelerating… ChatRWD outperforms tech giants in medical question-answering87% of pharma leaders say AI is crucial, Accenture study finds4 waves of NLP techniques and how to stitch them togetherWhat if AI makes good on its promise to reshape the pharma productivity?Sponsored Content See More >Leveraging HF/UX/ID Services to Optimize the Design of Combination Devices for Arthritic HandsBy Dr. Bryce G Rutter, Head of Consulting Services Arthritis changes how people grasp and manipulate an object, reducing the…Ask the Expert: Navigating the New FDA Rules on Laboratory Developed Tests (LDTs)The U.S. FDA released a final rule to regulate laboratory developed tests (LDTs) on May 6, 2024, making it clear…How tailored qPCR assays can unlock microbiome and precision medicine potential  Sponsored by Diversigen, Inc. Quantitative Polymerase Chain Reaction (qPCR) — also known as real-time PCR — is a molecular…Innovations in Baculovirus–Insect Cell Expression SystemsThe baculovirus–insect cell expression system—insect cells used in conjunction with the baculovirus expression vector system (BEVS)—remains a crucial technology for…Patient Training is Broken – And Everyone is Paying For ItNoble International is working with Pharma and Specialty Pharmacy to fix the problem. The report, “The Current Paradigm for Biologic…Noble Leads with its User-Centered Design StrategyBy Tim McLeroy, Executive Director of Marketing and Patient Services, Noble International At Noble, the patient journey drives everything we…Using Real-World Data to Address COVID-19By Cheryl Reifsnyder, PhD As a leading provider of data and advanced analytics, Veradigm understands the critical role real-world data…Discovering Antigen-specific Monoclonal Antibodies using Single B Cell ScreeningIntroduction Since the approval of Orthoclone OKT3 in 1986, more than 100 monoclonal antibodies (mAbs) have been approved by the…A new way to access scientific papers?Losing university access doesn’t mean losing access to articles anymore By DeepDyve Digital Library Team Many researchers are surprised to…These are not fireworks: The objective truthBy Jan Barghaan, Strategic Marketing Manager Life Science, Olympus Europa No, not fireworks — it’s actually a single colony of…AI technology automates tedious cell culture work and analysesBy Joanna Hawryluk, PhD, Product Manager, Olympus Life Science Since the early 20th century, cell culture has been considered the…What is Human AB serum?By Trevor Smith, MS MBA, Product Manager, Immune Cells Human AB Serum is a staple in the biological research field,…Genomics/Proteomics See More >St. Jude pioneers gene editing and structural biology to advance pediatric researchAfter establishing her lab at Cornell in 2019 and achieving notable success with publications in top journals, Liz Kellogg, Ph.D., associate member in the department of Structural Biology at St. Jude Children’s Research Hospital received a unique opportunity. St. Jude Children’s Research Hospital had embarked on a major expansion of its structural biology and genome… Helix and Recursion join forces in quest to crack the AI-driven drug discovery codeAthos Therapeutics chooses Vultr’s private cloud to power AI drug discovery engineDeep Genomics announces key hires, expands operations in Cambridge, Mass.Study combines biomimetic AI, digital twins and multiomics to unveil potential genetic drivers of endometriosisInfectious Disease See More >Moderna and Pfizer win approval for KP.2 vaccine as KP.3 variants account for about half of current casesThe FDA has approved Moderna’s and Pfizer’s updated COVID-19 vaccines targeting the KP.2 variant, an offshoot of the Omicron strain that was dominant in the U.S. in May 2024. More recently, KP.3 variants are gaining ground. As of August 20, 2024, CDC Nowcast projections estimate KP.3.1.1 accounts for approximately 37% of new COVID-19 cases in… Moderna’s single-dose mRNA RSV vaccine, mRESVIA, gains FDA approval for adults 60+Best-selling pharmaceuticals of 2023 reveal a shift in pharma landscapeLongevity biotech gaining momentum as demographic shifts drive demand for healthy agingPublic vs. private: Who’s leading the charge in H5N1 preparedness?Oncology See More >Scorpion’s STX-478 shows promising efficacy and tolerability in early cancer trialScorpion Therapeutics’ new oral cancer drug, STX-478, showed promising anti-tumor activity as a monotherapy in a Phase 1/2 trial, achieving an overall response rate (ORR) of 23% in breast cancer and 21% across all tumor types studied. The data were unveiled at the European Society for Medical Oncology (ESMO) Congress 2024, held 13–17 September 2024.… Kisqali slashes recurrence risk by 28.5% in early breast cancerEarli and Accenture partner in quest to turn cancer against itselfAI drug discovery space consolidates with $688M Recursion and Exscientia mergerBreakthrough FDA approval for first solid tumor cell therapy signals new era for cancer treatment  EXPAND YOUR KNOWLEDGE AND STAY CONNECTED Get the latest news and trends happening now in the drug discovery and development industry. GET THE ENEWSLETTER MEDTECH 100 INDEX Market Summary > Current Price The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing. Click for Index Details >> AI Meets Life Sci Connect with Drug Discovery & Development Drug Discovery and DevelopmentMassDevice DeviceTalks Medtech100 Index Medical Design Sourcing Medical Design & Outsourcing Medical Tubing + Extrusion Subscribe to our E-Newsletter Contact Us About Us R&D World Drug Delivery Business News Pharmaceutical Processing World Copyright © 2024 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media Privacy Policy | Advertising | About Us Search Drug Discovery & Development Home Drug Discovery and Development Drug Discovery Women in Pharma and Biotech Oncology Neurological Disease Infectious Disease Resources Video features Podcast Webinars Pharma 50 2024 Pharma 50 2023 Pharma 50 2022 Pharma 50 2021 Pharma 50enusen-US1729212361https://drugdiscoverytrends.com

Guhindura urubuga rwawe?

Uriko ukora iki?